Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle ... The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab) at its second attempt, having been turned down by the US regulator last year. The tissue ...

C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s concizumab, which will be sold under the brand name Alhemo, as a daily treatment to prevent or reduce the frequency of bleeding ...

highlighting Novo Nordisk’s commitment to patient-centric innovations in rare diseases.” Unlike many existing treatments that require intravenous infusions, concizumab-mtci is delivered through a ...

The study, “… A European Medicines Agency (EMA) committee has recommended the approval of Novo Nordisk’s concizumab as a prophylactic, or preventive, treatment for adults and children, ages 12 and ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...